Multipolarity and Globalization: A Shared Answer – International Media Discuss the Emerging Global Landscape
BEIJING, June 12, 2025 (GLOBE NEWSWIRE) -- The eighth 'International Editors-in-Chief Roundtable,' hosted by Global Times and Global Times Online (huanqiu.com), brought together media leaders from China, Russia, Pakistan, Canada, Nepal, Syria, and Ghana to explore global trends. Amid ongoing global shifts, participants highlighted the value of inclusive globalization and diversified cooperation.Muhammad Asif Noor, Editor-in-Chief of the Institute of Peace and Diplomatic Studies, Pakistan, said countries are adapting engagement models. Bai Long, Deputy Editor-in-Chief of the Global Times (China), stressed the importance of win-win development in a multipolar world. Liu Yonggang, President and Editor-in-Chief of The Paper, noted that 2024 marks a turning point in global economic restructuring, with developing countries gaining influence at COP28 and WTO talks.
Liu Hong, Deputy Editor-in-Chief of XinhuaNet, pointed to the Global Development Initiative and RCEP as key examples of inclusive multilateralism. Bai Long highlighted the Belt and Road Initiative's infrastructure impact.
Rituraj Subedi, Deputy Executive Editor of The Rising Nepal, said globalization is irreversible, and that cooperation and multilateralism are vital to fair growth.Company: huanqiu.com
Contact Person: Pang Zhiqin
Email:pangzhiqin@huanqiu.com
Website: www.huanqiu.com
Telephone: 0086-010-65361101
City: Beijing, China
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ab4fef92-fd04-4f71-ba32-02ca676e5b44
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Xcel Brands Announces Strategic Partnership with Global Fashion Icon Coco Rocha
Coco Rocha NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Xcel Brands (NASDAQ: XELB), an industry leading media and consumer products company specializing in building influencer-driven brands through social commerce and livestreaming, is proud to announce a groundbreaking new partnership with supermodel, advocate, and founder of Coco Rocha Model Camp, Coco Rocha. With more than two decades at the highest level of the fashion industry—having graced over 100 magazine covers, been shot by top photographers across the globe, and walked runways for luxury fashion houses ranging from Chanel, Louis Vuitton, John Galliano, Prada and Schiaparelli to Jean Paul Gaultier, Tom Ford, Moschino, and Marc Jacobs—Coco Rocha brings a rare depth of experience and insight to this collaboration. Rocha's illustrious career has granted her a front-row seat to the inner workings of the world's most legendary designers. Together, Coco Rocha and Xcel Brands will develop a bold, thoughtfully crafted fashion brand designed for women who lead with both strength and style. 'What excites me about partnering with Xcel is the opportunity to finally channel all of those unbelievable lived experiences into something of my own,' said Rocha. 'This isn't about chasing trends or putting my name on a label—it's about designing elevated essentials that reflect the life I live now as a mother, businesswoman, and creative.' This collaboration aims to speak to women seeking pieces that feel as powerful and dynamic as their daily lives. Coco Rocha's collection will deliver runway-inspired elegance with everyday practicality. Robert W. D'Loren, Chairman and CEO of Xcel Brands, said, 'Coco Rocha is one of the most influential fashion figures of our time. Her perspective, creativity, and commitment to authenticity make her the perfect partner for our next brand launch. We are thrilled to work alongside her in building something empowering and extraordinary.' This announcement further pushes Xcel's commitment to redefining modern fashion through innovative partnerships with authentic, visionary creators. For more information, visit About Xcel BrandsXcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel owns the Halston, Judith Ripka, and C. Wonder brands, as well as the co-branded collaboration brands TowerHill by Christie Brinkley, LB70 by Lloyd Boston, Trust. Respect. Love. by Cesar Millan, and GemmaMade by Gemma Stafford, and also holds noncontrolling interests or long-term license agreements in the Isaac Mizrahi brand, Orme Live and Jenny Martinez Live brands. Xcel also owns and manages the Longaberger brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a true modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customers shop. The company's brands have generated in excess of $5 billion in retail sales via livestreaming in interactive television and digital channels alone and consisting of over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches in excess of 40 million social media followers with broadcast reach into 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit About Coco Rocha Coco Rocha is an internationally acclaimed supermodel, entrepreneur, and educator who has redefined the role of a model through two decades of innovation and influence. Named Model of the Year by Elle and Marie Claire, and hailed by Vogue Paris and Vogue Italia as one of the top models of all time, she has graced the runways of every major fashion house and appeared in countless international campaigns and covers. Widely known as the "Queen of Pose", Coco is considered one of the most technically proficient and versatile models of her generation. In 2014, she authored Study of Pose, a 2,000-page visual encyclopedia that has become a go-to reference for models and photographers alike. A pioneer in digital influence, Coco was the first high-fashion model to fully embrace social media—amassing millions of followers and earning recognition from Time magazine and TikTok as a leading voice in fashion. An outspoken advocate for model rights, she played a pivotal role in passing legislation in New York to protect underage models. In 2018, she launched the Coco Rocha Model Camp (CRMC), a first-of-its-kind program offering hands-on modeling training combined with career and business strategy. Nearly 5,000 students have trained under Coco—including Kendall Jenner, Alix Earle, Bryce Dallas Howard, Dixie D'Amelio, Tabria Majors, and more. She has shared her expertise through guest lectures at Harvard, Brown, and SCAD, and co-founded Nomad MGMT, a boutique modeling agency with offices in three countries. Beyond fashion, Coco is an active investor and advisor to early-stage startups in tech, media, and commerce. She lives in New York with her husband and creative partner, James Conran, and their three Rocha is represented by The Lions further information, please contact:Seth Burroughs Xcel Brands sburroughs@ For press inquiries with Coco Rocha, please contact:Bianca A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved a label expansion for Illuccix® (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include patient selection for radioligand therapy (RLT) in the pre-taxane setting. The update applies to Illuccix's third indication, for selection of patients who are indicated for PSMA1-directed therapy as described in the Prescribing Information of the therapeutic products. The label expansion follows the FDA's approval of an expanded label for Pluvicto®2 (lutetium Lu177 vipivotide tetraxetan) for use in metastatic castration-resistant prostate cancer (mCRPC) patients after treatment with androgen receptor pathway inhibitor (ARPI) therapy and before chemotherapy3. With RLT now approved for use earlier in the patient journey, the clinical utilization of Illuccix® is expected to increase by at least 20,000 scans annually4. Scott T. Tagawa, MD, a genitourinary (GU) oncologist in New York said, 'It is pleasing to see the ability to use gallium-68 PSMA-PET for patient selection expanded. This empowers clinicians to make more informed, personalized decisions earlier in the disease course and access life-prolonging targeted radionuclide therapy for more patients with prostate cancer.' Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, said, 'We're pleased that the U.S. label for Illuccix has been expanded to support patient selection for RLT in the pre-taxane setting, aligning with the evolving treatment landscape. PSMA-PET imaging has become a standard of care in the detection and management of prostate cancer. With this update, patients can now benefit from the high diagnostic accuracy of Illuccix to identify those most likely to respond to PSMA-targeted therapy, even earlier in their treatment journey.' INDICATIONS AND USAGE Illuccix, after radiolabeling with Ga 68, is for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level For selection of patients who are indicated for PSMA-directed therapy as described in the Prescribing Information of the therapeutic products IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONS Risk for MisinterpretationImage interpretation errors can occur with Illuccix PET. A negative image does not rule out the presence of prostate cancer, and a positive image does not confirm the presence of prostate cancer. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. Imaging Prior to Initial Definitive or Suspected Recurrence TherapyThe performance of Illuccix for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of Illuccix for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score. Radiation RisksGallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and healthcare providers. Advise patients to hydrate before and after administration and to void frequently after administration. ADVERSE REACTIONSThe safety of gallium Ga 68 gozetotide was evaluated in 960 patients in the PSMA-PreRP and PSMA-BCR studies, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of <1%.In the VISION study, 1003 patients received one dose of gallium Ga 68 gozetotide intravenously with the amount of radioactivity 167.1 ± 23.1 MBq (4.52 ± 0.62 mCi). Adverse reactions occurring at ≥0.5% in patients with metastatic prostate cancer who received gallium Ga 68 gozetotide injection in the clinical study were fatigue (1.2%), nausea (0.8%), constipation (0.5%), and vomiting (0.5%). Adverse reactions occurring at a rate of < 0.5% in the VISION study were diarrhea, dry mouth, injection site reactions, including injection site hematoma and injection site warmth and chills. DRUG INTERACTIONSAndrogen deprivation therapy and other therapies targeting the androgen pathwayAndrogen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established. Please note that this information is not see the Full Prescribing Information . You are encouraged to report suspected adverse reactions of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing: pharmacovigilance@ Dr. Tagawa has served as a paid consultant to Telix and his institution has received research funding. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Telix Media Relations (U.S.) Eliza Schleifstein ES Media Relations Email: eliza@ Phone: 917-763-8106 About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's first generation PSMA-PET imaging agent, is approved and commercially available in multiple countries globally. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the U.S. FDA5. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. _________________________1 Prostate-specific membrane antigen2 Pluvicto is a registered trademark of Novartis AG and/or its affiliates.3 28 March 2025, FDA Statement: for patients who have been treated with ARPI therapy and are considered appropriate to delay taxane-based chemotherapy.4 Based on licensed indication for Pluvicto in mCRPC patients who have been treated with androgen receptor (AR) pathway inhibition.5 Telix ASX disclosure 21 March 2025.
Hamilton Spectator
2 hours ago
- Hamilton Spectator
Triple Hair Group Signs Licensing Agreement for the Brazilian Market with Aché
MONTRÉAL, June 23, 2025 (GLOBE NEWSWIRE) — Triple Hair Group Inc. ('Triple Hair' or the 'Company'), a company specializing in the development of innovative treatments for androgenic alopecia, is pleased to announce that it has signed a licensing agreement with Aché Laboratórios Farmacêuticos S.A. ('Aché'), granting Aché exclusive rights to sell Triple Hair's Therapy-07 prescription drug in Brazil. The agreement consists firstly of upfront and milestone payments. Additional revenues will be generated through royalties from potential future sales of Therapy‑07 in the Brazilian market. 'This partnership marks a major milestone for Triple Hair,' said Jean-Philippe Gravel, President and CEO of Triple Hair. 'Aché is one of Brazil's leading pharmaceutical companies, with a strong track record in the commercialization of dermatology products for hair loss. With a top-selling minoxidil-based product already on the market, a robust sales force, and an extensive network of physicians, Aché is ideally positioned to promote and grow our brand in Brazil.' According to a report published by Statista, the Brazilian hair care market is the fourth largest in the world, with projected revenue of US$6 billion for 2025. About Aché Aché is a Brazilian pharmaceutical company founded nearly 60 years ago with a mission to improve people's lives. A leader in the prescription market in Brazil, Aché's portfolio also includes solutions in generic medicines and over-the-counter (OTC) products. This success is driven by a commitment to excellence and a focus on investments in in-house research and development (R&D), partnerships for open innovation, and in-licensed products. Aché is recognized as a top-of-mind company and a brand of choice among Brazilian healthcare professionals, with over 350 brands and 900 drug presentations across more than 150 therapeutic categories and 30 medical specialties. Today, Aché's products reach more than 20 countries across Latin America, Africa, Asia, and Europe, in addition to its home base in Brazil. About Triple Hair Triple Hair Group Inc. is a Canadian biotechnology company dedicated to developing innovative, clinically proven treatments for men and women suffering from androgenic alopecia. Triple Hair's mission is to provide effective prescription hair regrowth treatments for an underserved global market valued at US$8.8 billion in 2023, and expected to reach US$16 billion by 2030. Triple Hair also offers patented over-the-counter natural hair growth products under its RIZN™ and Plenty Natural™ brands. For more information, visit the Company's website, at . Contact: This press release may contain forward-looking statements, which are subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what the Company currently expects. Therefore, future events and results may vary significantly from what management currently foresees. The reader should not place undue importance on forward-looking information and should not rely upon this information as of any other date.
